FDA allows imports of syphilis drug alternate during shortage
时间:2024-06-29 03:19:41 阅读(143)
US regulators gave temporary permission for importation of a form of penicillin used to treat syphilis amid a national shortage of Pfizer Inc.’s version of the drug along with a dramatic increase in cases.
The Food and Drug Administration authorized importation of penicillin G benzathine made by a French company, Laboratoires Delbert, according to the agency website. Pfizer’s Bicillin L-A, the only version of the drug available in the US, has been in short supply since April.
While as little as one injection of penicillin G benzathine can cure syphilis, the shortage prompted US health officials to recommend giving some patients doxycycline, another antibiotic therapy that requires of weeks of twice-daily pills. The long treatment regimen raises the risk that patients might not complete it, leaving them sick and potentially infectious to others.
The National Coalition of STD Directors applauded the FDA’s action. “We hope this is the first step toward seeing a resolution to this shortage,” David Harvey, executive director of NCSD, said in a statement. Harvey had previously criticized the federal government’s response.
To fix the shortage, Pfizer has added manufacturing shifts and more than halved production time. The company has invited customers who are having trouble getting the drug to contact them directly. “We continue to supply the market above historical rates, and we are reserving product for emergency needs,” a Pfizer spokesperson said.
The shortage is estimated to last through June, according to the FDA.
Unlike Pfizer’s prefilled syringe, Laboratoires Delbert’s formulation of the drug is a powder that must be mixed and then injected by a health-care provider.
上一篇:Rating- ADD - IDFC First Bank- Strong deposit growth
下一篇:YashoBhoomi Convention Centre- A look inside world’s finest state-of-the-art facilities – See Pics
猜你喜欢
- Centre may provide Rs 12-14k crore more for MGNREGS this fiscal
- Ram Temple consecration likely to generate Rs 50,000 crore trade in January- CAIT
- FIDC tells NBFCs to enhance responsible lending behaviour
- F&O expiry outlook August 25- Good time to book profits, market in overbought zone with support at 17800-17700
- Buy Reliance Industries stock- RIL share may soar above Rs 2600; charts signal technical pullback in near-term
- F&O expiry- Nifty to trade in 17400-17600 range, Bank Nifty may hit 37300; check trading strategy
- Rainbow Children’s Medicare shares list at discount to IPO price, down 6
- F&O weekly expiry- Nifty support at 17442, Bank Nifty needs to hold 38250 for up move; buy IRCTC, ICICI Bank
- Rating- buy; Tata Motors expects India biz to recover